Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth? - 2Sintana Energy flags major resource upgrade at Namibia oil discovery
- 3Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- 4German foreign minister backs abandoning EU's unanimity principle
- 5The Way to Monetary Freedom: A Viable Aide
- 'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1
- Are Saturn's rings made of a lost, shattered moon? New evidence arises for the case
- Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- 5 Great High-Mileage Electric Vehicles Of 2024
- 5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
